PCM
STRO icon

Pinz Capital Management’s Sutro Biopharma STRO Stock Holding History

Pinz Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,780
Closed -$2.99M – 366
2020
Q4 		$2.99M Buy
+13,780
New +$2.28M 1.36% 26

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Pinz Capital Management's STRO Position: Q1 2021 in Review

Pinz Capital Management sold out of Sutro Biopharma (STRO) in Q1 2021, closing a stake of 13,780 shares — an estimated $2.99M sold.

Pinz Capital Management first reported a position in STRO in Q4 2020 and held it in 1 quarter. The position peaked at $2.99M in Q4 2020. 138 funds tracked by Wall St. Rank hold STRO as of Q1 2021.

  • Pinz Capital Management reported no remaining Sutro Biopharma position as of Q1 2021 after selling out during the quarter.
  • Pinz Capital Management sold 13,780 Sutro Biopharma shares in Q1 2021, an estimated $2.99M.
  • Pinz Capital Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 1 quarter.
  • Pinz Capital Management's Sutro Biopharma position peaked at $2.99M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2021.

Based on Pinz Capital Management's 13F filing for Q1 2021, filed 17 May 2021.